AbbVie Inc. is trading at all-time highs with a market cap over $500 billion, supported by robust 2026 guidance. The company's Q3 earnings are expected to outperform, mainly due to strong sales from immunology drugs Skyrizi and Rinvoq, projected to generate over $30 billion in 2026. Despite concerns about an aging product portfolio and pipeline depth, AbbVie's near-term growth and profit margins remain among the best in the industry, justifying a higher valuation. While potential pricing pressures and pipeline risks exist long-term, AbbVie's current fundamentals and cash flow support a positive investment outlook.
AbbVie shares are trading near their 52-week high at USD 286.99 on Pluang as of Oct 27, 2026 23:41 WIB, showing a slight 0.07% increase in the last day. The company's market capitalization stands at $506.70 billion, reflecting its large scale in the health sector. Investor interest remains strong with 88% of Pluang order activity on the buy side, indicating confidence in AbbVie's prospects.
AbbVie has submitted a Biologics License Application to the FDA for etentamig, a second-generation bispecific antibody T-cell engager for relapsed or refractory multiple myeloma. In the Phase 3 CERVINO study, etentamig demonstrated significant improv...
AbbVie will report its Q3 2026 earnings before market open on October 30, with shares up 28.55% year to date. Options pricing suggests a roughly 5% price move around the release, indicating high expectations. The company recently trimmed its full-yea...
The FDA has approved a new subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) to treat adults with moderately to severely active Crohn's disease. This allows patients to start treatment at home using an on-body injector (OBI) device, impr...
